• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria

byStudy Graphics | C.WuandConstance Wu
September 6, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. After initial chloroquine treatment, P. vivax malaria infected patients treated with tafenoquine had significantly lower rates of P. vivax infection at 6 months compared to patients given placebo.

2. Mean hemoglobin levels were mildly reduced in the tafenoquine group but returned to baseline after treatment.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: P. vivax, one of the causative pathogens of malaria, can infect a substantial portion of the world population and be difficult to completely treat due to different life stages of the parasite. Generally, chloroquine is used to treat asexual parasites and a subsequent 14-day treatment with a primaquine clears hypnozoites. Due to adherence difficulties, a shorter course of treatment for hypnozoites is sought. This study evaluated clearance of P. vivax infection in patients treated with chloroquine followed by a single dose of the long acting drug tafenoquine, placebo, or a 14-day regimen of primaquine. After 6 months, patients treated with tafenoquine had a significantly lower relapse for infection rate than those treated with placebo, and had a comparable relapse rate as those in the primaquine group. Hemoglobin levels were mildly lower for a brief period after tafenoquine treatment but returned to baseline in all patients.

This study supports use of a single dose treatment for clearance of hypnozoites in P. vivax malaria infected patients. Though the study is limited in the number of patients included and subsequent hazard ratios for various outcomes were often large, results were conclusive across all subgroups assessed that tafenoquine is substantially more effective than placebo after chloroquine treatment.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

RELATED REPORTS

Monoclonal antibody CIS43LS efficacious in preventing malaria in Mali

Monoclonal antibody L9LS prevents malaria infection in adults

Higher-dose primaquine has higher efficacy in preventing relapse of Plasmodium vivax malaria

Tags: malariaP. vivaxtafenoquine
Previous Post

Quick Take: Accelerated hypofractionated radiation therapy for elderly frail bladder cancer patients unfit for surgery or chemotherapy

Next Post

Quick Take: Prior dengue virus infection and risk of Zika: a pediatric cohort in Nicaragua

RelatedReports

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time
Infectious Disease

Monoclonal antibody CIS43LS efficacious in preventing malaria in Mali

November 23, 2022
Intrauterine Zika virus infection associated with significant fetal brain abnormalities
Chronic Disease

Monoclonal antibody L9LS prevents malaria infection in adults

August 11, 2022
RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time
Chronic Disease

Higher-dose primaquine has higher efficacy in preventing relapse of Plasmodium vivax malaria

April 22, 2022
RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time
Infectious Disease

Chlorfenapyr insecticidal nets provide strong protection against malaria in sub-Saharan Africa

April 6, 2022
Next Post
Intrauterine Zika virus infection associated with significant fetal brain abnormalities

Quick Take: Prior dengue virus infection and risk of Zika: a pediatric cohort in Nicaragua

Transthoracic echocardiography can rule out endocarditis in low-risk bacteremic patients

The OVIVA trial: oral antibiotics noninferior to intravenous antibiotics for bone and joint infections

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

The PIVOTOL trial: high-dose iron reduces incidence of serious adverse events in hemodialysis patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options